CN107760652A - CRISPR/CAS9介导药物转运体靶向性敲除的caco‑2细胞模型及其方法 - Google Patents
CRISPR/CAS9介导药物转运体靶向性敲除的caco‑2细胞模型及其方法 Download PDFInfo
- Publication number
- CN107760652A CN107760652A CN201710911586.0A CN201710911586A CN107760652A CN 107760652 A CN107760652 A CN 107760652A CN 201710911586 A CN201710911586 A CN 201710911586A CN 107760652 A CN107760652 A CN 107760652A
- Authority
- CN
- China
- Prior art keywords
- caco
- sgrna
- crispr
- transporter
- cas9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
Abstract
本发明公开了CRISPR/CAS9介导药物转运体靶向性敲除的caco‑2细胞模型及其方法,该方法用于非诊断或治疗目的,包括如下步骤:对P‑gp、BCRP及MRP2转运体设计靶点特异性的sgRNA,设计的sgRNA序列如序列表中SEQ ID NO:1‑6所示,构建sgRNA表达载体;利用CRISPR/CAS9分别设计P‑gp、BCRP及MRP基因单敲除及两两组合双敲除,与hCas9质粒共转染caco‑2细胞,进行单克隆化扩大培养,即得转运体基因靶向性的caco‑2细胞模型。本发明获得的caco‑2细胞模型将有效排除不同转运体之间相互干扰,为药物转运研究提供更特异、更灵敏的细胞模型。
Description
技术领域
本发明涉及基因工程领域,具体涉及CRISPR/CAS9介导药物转运体靶向性敲除的caco-2细胞模型及其方法。
背景技术
药物转运研究是新药研发过程的重要内容。转运体,通过转运体进行继发性主动转运,即依靠存在于细胞外高浓度钠离子的势能(该势能由原发性主动转运提供)转运,即相当于间接消耗ATP的能量。例如小肠粘膜上皮细胞主动吸收葡萄糖的过程中,转运能量并不直接来自于ATP的分解,而是依靠上皮细胞(低)与肠腔液(高)之间的钠离子浓度梯度,在钠离子顺浓度梯度进入上皮细胞的同时,葡萄糖逆浓度梯度一同被转运进细胞。ATP结合转运体家族主要成员P-gp、BCRP及MRP2参与大量化合物转运,是目前常用候选转运体。然而三者底物及抑制剂的交叉反应严重影响结果分析。
CRISPR-Cas9具有更快速、简便、高效、多位点、特异性靶向敲除基因的优势。CRISPR-Cas9的工作原理是crRNA(CRISPR-derived RNA)通过碱基配对与tracrRNA(trans-activating RNA)结合形成tracrRNA/crRNA复合物,此复合物引导核酸酶Cas9蛋白在与crRNA配对的序列靶位点剪切双链DNA。而通过人工设计这两种RNA,可以改造形成具有引导作用的sgRNA(singleguide RNA),足以引导Cas9对DNA的定点切割。作为一种RNA导向的dsDNA结合蛋白,Cas9效应物核酸酶是已知的第一个统一因子(unifying factor),能够共定位RNA、DNA和蛋白,从而拥有巨大的改造潜力。将蛋白与无核酸酶的Cas9(Cas9nuclease-null)融合,并表达适当的sgRNA,可靶定任何dsDNA序列,而sgRNA的末端可连接到目标DNA,不影响Cas9的结合。因此,Cas9能在任何dsDNA序列处带来任何融合蛋白及RNA,这为生物体的研究和改造带来巨大潜力。也为解决上述问题提供了一种可能的选择。
发明内容
本发明的目的在于提供CRISPR/CAS9介导药物转运体靶向性敲除caco-2细胞模型及其方法,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案。
CRISPR/CAS9介导药物转运体靶向性敲除caco-2细胞模型的方法,该方法用于非诊断或治疗目的,包括如下步骤:
1)对P-gp、BCRP及MRP2转运体设计靶点特异性的sgRNA,设计的sgRNA序列如序列表中SEQ ID NO:1-SEQ ID NO:6所示,构建sgRNA表达载体;
2)利用CRISPR/CAS9分别设计P-gp、BCRP及MRP基因单敲除及两两组合双敲除,与hCas9质粒共转染caco-2细胞,进行单克隆化扩大培养,即得转运体基因靶向性的caco-2细胞模型。
优选的,步骤1)中,以U6启动子表达sgRNA,将设计的sgRNA序列合成Oligo,构建sgRNA表达载体。
本发明还提供由以上方法得到的caco-2细胞模型。
与现有技术相比,本发明的有益效果是:
本发明通过CRISPR/CAS9结合细胞单克隆技术,对ABC家族P-gp、BCRP及MRP进行了系列单敲除或双敲除,获得一系列基因敲除的caco-2细胞模型。该caco-2细胞模型将有效排除不同转运体之间相互干扰,为药物转运研究提供更特异、更灵敏的细胞模型。
附图说明
图1是靶位点PCR产物T7EI酶切后电泳结果图;
图2a是caco-2细胞单克隆(2A10)的示意图;
图2b是caco-2细胞单克隆(B14)的示意图;
图2c是caco-2细胞单克隆(2M1)的示意图;
图3是2A10单克隆敲除纯合子鉴定结果图;
图4是B14单克隆敲除纯合子鉴定结果图;
图5是2M1单克隆为2种基因型的敲除纯合子鉴定结果图;
图6是AM17单克隆的MRP2位点2种基因型的敲除纯合子鉴定结果图;
图7是AB16单克隆的BCRP位点敲除纯合子鉴定结果图;
图8是MB11单克隆的BCRP位点2种基因型敲除纯合子鉴定结果图;
图9a、图9b是单克隆细胞P-gp和MRP2转运体蛋白表达检测结果图;
图10是AB5和2A10单克隆的P-gp转运功能分析结果图。
具体实施方式
下面结合附图与实施例对本发明的具体实施作进一步的说明,但本发明的实施方式不限于此。
实施例1
本发明实施例中,CRISPR/CAS9介导药物转运体靶向性敲除caco-2细胞模型的方法,该方法用于非诊断或治疗目的,具体包括如下步骤:
1.针对ABC家族主要成员P-gp、BCRP及MRP2设计靶点特异性的sgRNA,构建其表达载体,并进行基因敲除有效性检测。
分别针对P-gp(NG_011513.1-ABCB1-Pgp)、BCRP(NG_032067.2-ABCG2-BCRP)及MRP2(NG_011798.1-ABCC2-MRP2)的基因表达功能区,设计特异性sgRNA,并进行脱靶分析。每个基因筛选两条特异性好、脱靶低的sgRNA,P-gp、BCRP及MRP2的sgRNA设计结果如表1所示。
表1
以U6启动子表达sgRNA,将设计的sgRNA序列合成Oligo,构建sgRNA表达载体U6-sgRNA。经测序分析均构建成功。
U6-sgRNA质粒构建过程:
(1)设计的sgRNA合成Oligo,正义链(即与靶位点相同的序列):5’-CACC-GN19-3’,反义链:5’-AAAC-19NC-3’(反义链N19为正义链N19的反向互补序列);
(2)2Oligo退火;U6进行BbsI酶切线性化,37℃反应2hr,切胶回收线性化片段;
(3)退火的Oligo与线性化U6酶切产物连接过夜;连接产物转化DH5α感受态细胞,涂布于含卡那霉素的LB平板生长,挑取单菌落于1mL LB液体培养基中(含卡那),37℃培养2~3h,采用sp6引物和正义链进行菌落PCR;菌落PCR为阳性的单克隆菌进行测序鉴定。测序引物为sp6。序列正确者进行扩大培养和质粒制备。
选择A26f,A154f,B88f,B172r,M38r,M70r sgRNA表达质粒与hCas9质粒共转染293T细胞,72h后提取基因组进行靶位点扩增,PCR产物进行T7EI酶切鉴定。酶切产物电泳显示,A26f有2条带,较浅,A154f有3条带,较浅,B88f有三条目地条带,B172r有2条目地条带,较浅,M38r有3条带,较清晰,M70r有三条带较清晰,如图1所示,其中A26f,A154f,B88f,B172r,M38r,M70r为sgRNA切割组,WT为未切割的野生型,M为DL2000marker。图1表明设计构建的sgRNA均能有效切割靶点。
转染293T细胞过程:
A26f,A154f,B88f,B172r,M38r,M70rsgRNA表达质粒与H-Cas9质粒共转染293T细胞(采用脂质体转染方法),转染步骤具体如下:
(1)弃去旧培养基,加入2ml新鲜培养基进行孵育;
(2)取1ug sgRNA重组质粒和1ug hCas9质粒溶于100ul DMEM(H)中,取6ul脂质体转染试剂稀释至100ul,将稀释的脂质体转染试剂加入到质粒稀释液中,轻轻吹均匀,配成转染复合物,常温反应15min;
(3)将转染复合物滴入6well中,37℃反应5h,弃去反应液,加入新鲜培养基培养。
基因组提取过程:
(1)转染72h后,60mm dish 293T细胞全部0.25%胰酶消化,1000rpm离心3min,弃上清;
(2)加入1ml PBS重悬,转移到1.5ml离心管中,1000rpm离心3min弃上清,加入200ul PBS悬浮细胞;
(3)基因组提取试剂盒裂解法提取基因组DNA,最后用40ul DDH2O洗脱;
(4)DNA浓度测定;
(5)基因组DNA1%琼脂糖凝胶电泳。
靶点扩增:
以转染后提前的基因组为模板,对A26f,A154f,B88f,B172r,M38r,M70r进行PCR扩增;以野生型为模板,同样扩增A26f-wt,A154-wt,B88f-wt,B172r-wt,M38r-wt,M70r-wt,扩增引物如表2
表2
PCR扩增反应程序:95℃3min;95℃45s,61℃45s,72℃30s,30个循环;72℃5min;4℃保存。
T7EI酶切检测过程:
(1)使用PCR产物,取200ng统一稀释到20μl进行变性、退火,程序如:95℃,5min;95–85℃at-2℃/s;85–25℃at-0.1℃/s;hold at 4℃。
(2)在20μl体系中加入T7EN1 0.3μl,37℃酶切30分钟后,加入2μl 10X LoadingBuffer(上样缓冲液),用2%的琼脂糖胶电泳检测。
2.P-gp、BCRP及MRP基因靶向性敲除caco-2单克隆细胞建立及鉴定
分别设计P-gp、BCRP及MRP基因单敲除及两两组合双敲除,分别将构建U6-sgRNA质粒与hCas9质粒共转染caco-2细胞,72h后加800ug/ml G418筛选,每2天换药一次,7天后消化消化细胞,有限稀释法稀释细胞,以100个细胞每孔的密度铺5个10cm平皿,15天待单克隆细胞长至0.5cm,可进行挑取。挑取细胞单克隆至24孔板培养,长满后取1/10细胞鉴定基因型,9/10的细胞传至12孔板,进行单克隆细胞扩大培养,长满后冻存。经测序鉴定,获得一系列单克隆敲除细胞,部分如P-gp敲除细胞2A10;BCRP敲除细胞B14,MRP2敲除细胞2M1,(见图2a、图2b、图2c、)。
(1)单克隆细胞扩大培养后,以表2的引物分别进行PCR扩增及测序鉴定。部分鉴定结果如图3-图8所示,其中图3是表1中A154f的sgRNA序列获得的2A10敲除纯合子鉴定结果图;图4是表1中B88f的sgRNA序列获得的B14敲除纯合子鉴定结果图;图5是表1中M70r的sgRNA序列获得的2M1敲除纯合子鉴定结果图;图6是表1中A154f和M70r的sgRNA序列获得AM17单克隆的MRP2位点2种基因型的敲除纯合子鉴定结果图;图7是表1中A154f和B88f的sgRNA序列获得AB16单克隆的BCRP位点敲除纯合子鉴定结果图;图8是表1中M70r和B88f的sgRNA序列获得MB11单克隆的BCRP位点2种基因型敲除纯合子鉴定结果图。
(2)敲除后转运体蛋白表达检测,部分结果如图9a、图9b所示,AB5由表1中A154f和B88f的sgRNA序列获得,AM3由表1中A154f和M70r的sgRNA序列获得,A9和2A10由表1中A154f的sgRNA序列获得,2M1、M10由表1中M70r的sgRNA序列获得,BM8和BM9由表1中B88f和M70r的sgRNA序列获得。与野生型相比较,部分基因敲除后的单克隆细胞未见转运体蛋白的表达,表明已经获得转运体基因敲除细胞模型。
(3)基因敲除后转运体功能分析
选择转运体特异性的底物,采用transwell系统对转运体进行药物转运分析,如图10所示。结果发现基因敲除后细胞系转运体的转运功能基本缺失。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
序列表
<110> 华南理工大学
<120> CRISPR/CAS9介导药物转运体靶向性敲除的caco-2细胞模型及其方法
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> DNA
<213> caco-2细胞(A26f)
<400> 1
gatcttgaag gggaccgcaa tgg 23
<210> 2
<211> 23
<212> DNA
<213> caco-2细胞(A154f)
<400> 2
ttggcttgac aagttgtata tgg 23
<210> 3
<211> 23
<212> DNA
<213> caco-2细胞(B88f)
<400> 3
gacagcttcc aatgacctga agg 23
<210> 4
<211> 23
<212> DNA
<213> caco-2细胞(B172r)
<400> 4
gataatattt ctttctcaac tgg 23
<210> 5
<211> 23
<212> DNA
<213> caco-2细胞(M38r)
<400> 5
ctccggactg tccaggaatg agg 23
<210> 6
<211> 23
<212> DNA
<213> caco-2细胞(M70r)
<400> 6
acagtttgct caaaacaaag tgg 23
Claims (3)
1.CRISPR/CAS9介导药物转运体靶向性敲除caco-2细胞模型的方法,其特征在于,包括如下步骤:
1)对P-gp、BCRP及MRP2转运体设计靶点特异性的sgRNA,设计的sgRNA的序列如序列表中SEQ ID NO:1- SEQ ID NO:6所示,再构建sgRNA表达载体;
2)利用CRISPR/CAS9分别设计P-gp、BCRP及MRP基因单敲除及两两组合双敲除,与hCas9质粒共转染caco-2细胞,进行单克隆化扩大培养,即得转运体基因靶向性的caco-2细胞模型。
2.根据权利要求1所述的CRISPR/CAS9介导药物转运体靶向性敲除caco-2细胞模型的方法,其特征在于,步骤1)中,以U6启动子表达sgRNA,将设计的sgRNA序列合成Oligo,构建sgRNA表达载体。
3.由权利要求1-2任一所述方法得到的caco-2细胞模型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710911586.0A CN107760652A (zh) | 2017-09-29 | 2017-09-29 | CRISPR/CAS9介导药物转运体靶向性敲除的caco‑2细胞模型及其方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710911586.0A CN107760652A (zh) | 2017-09-29 | 2017-09-29 | CRISPR/CAS9介导药物转运体靶向性敲除的caco‑2细胞模型及其方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107760652A true CN107760652A (zh) | 2018-03-06 |
Family
ID=61267373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710911586.0A Pending CN107760652A (zh) | 2017-09-29 | 2017-09-29 | CRISPR/CAS9介导药物转运体靶向性敲除的caco‑2细胞模型及其方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107760652A (zh) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1661040A (zh) * | 2004-12-29 | 2005-08-31 | 华东师范大学 | 一种抗转运蛋白类介导的肿瘤多药耐药逆转剂的筛选方法及应用 |
CN103820441A (zh) * | 2014-03-04 | 2014-05-28 | 黄行许 | CRISPR-Cas9特异性敲除人CTLA4基因的方法以及用于特异性靶向CTLA4基因的sgRNA |
CN105907721A (zh) * | 2016-05-13 | 2016-08-31 | 广东省农业科学院农业生物基因研究中心 | 一种稳定表达Cas9蛋白的猪肠道上皮细胞系 |
CN106480097A (zh) * | 2016-10-13 | 2017-03-08 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用 |
CN106834347A (zh) * | 2016-12-27 | 2017-06-13 | 安徽省农业科学院畜牧兽医研究所 | 一种山羊cdk2基因敲除载体及其构建方法 |
-
2017
- 2017-09-29 CN CN201710911586.0A patent/CN107760652A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1661040A (zh) * | 2004-12-29 | 2005-08-31 | 华东师范大学 | 一种抗转运蛋白类介导的肿瘤多药耐药逆转剂的筛选方法及应用 |
CN103820441A (zh) * | 2014-03-04 | 2014-05-28 | 黄行许 | CRISPR-Cas9特异性敲除人CTLA4基因的方法以及用于特异性靶向CTLA4基因的sgRNA |
CN105907721A (zh) * | 2016-05-13 | 2016-08-31 | 广东省农业科学院农业生物基因研究中心 | 一种稳定表达Cas9蛋白的猪肠道上皮细胞系 |
CN106480097A (zh) * | 2016-10-13 | 2017-03-08 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用 |
CN106834347A (zh) * | 2016-12-27 | 2017-06-13 | 安徽省农业科学院畜牧兽医研究所 | 一种山羊cdk2基因敲除载体及其构建方法 |
Non-Patent Citations (7)
Title |
---|
KITADA K等: "Homo sapiens ATP binding cassette subfamily B member 1 (ABCB1),RefSeqGene on chromosome 7", 《GENBANK》 * |
NCBI: "Homo sapiens ATP binding cassette subfamily G member 2 (Junior blood group) (ABCG2),RefSeqGene on chromosome 4", 《GENBANK》 * |
ZHANG Y等: "Homo sapiens ATP binding cassette subfamily C member 2 (ABCC2),RefSeqGene on chromosome 10", 《GENBANK》 * |
尤海生等: "野黄芩苷和野黄芩素在Caco-2细胞模型中的吸收转运特性", 《中西医结合学报》 * |
张惠展: "《基因工程 第4版》", 31 January 2017 * |
陈洪岩等: "《实验动物学概论》", 30 June 2016, 吉林人民出版社 * |
龚淑敏等: "慢病毒载体介导的RNAi双敲除ABCG2和UGT1A1的Caco-2细胞模型", 《天津医科大学学报》 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107760652A (zh) | CRISPR/CAS9介导药物转运体靶向性敲除的caco‑2细胞模型及其方法 | |
AU2020267249B2 (en) | Genome editing using campylobacter jejuni crispr/cas system-derived rgen | |
CN107502608B (zh) | 用于敲除人ALDH2基因的sgRNA、ALDH2基因缺失细胞株的构建方法及应用 | |
JP6937740B2 (ja) | ゲノム編集システムおよび使用方法 | |
JP6814141B2 (ja) | 真菌ゲノム改変システムおよび使用方法 | |
Bullock et al. | Association of crossover points with topoisomerase I cleavage sites: a model for nonhomologous recombination | |
CN104560742B (zh) | 农杆菌介导茭白黑粉菌转化子菌株及其制备方法和应用 | |
WO2019018423A1 (en) | NEW TYPE VI CRISPR ORTHOLOGISTS AND ASSOCIATED SYSTEMS | |
CN106906242A (zh) | 一种提高CRIPSR/Cas9靶向敲除基因产生非同源性末端接合效率的方法 | |
WO2019005866A1 (en) | NEW TYPE VI CRISPR ORTHOLOGISTS AND ASSOCIATED SYSTEMS | |
CA3028158A1 (en) | Type vi crispr orthologs and systems | |
CN108642055A (zh) | 能有效编辑猪miR-17-92基因簇的sgRNA | |
WO2016205764A9 (en) | Novel crispr enzymes and systems | |
CN106414740A (zh) | CRISPR‑Cas9特异性敲除猪SLA‑3基因的方法及用于特异性靶向SLA‑3基因的sgRNA | |
US11795475B2 (en) | Cell strain for reducing production of replication competent adenovirus, and construction method and use thereof | |
US11866703B2 (en) | Method for knocking out N-myristoyltransferase (NMT) gene from Eimeria tenella | |
CN106755089A (zh) | 表达山羊淋巴细胞活化分子的细胞系及其构建方法与应用 | |
CN107177592A (zh) | 抑制性tRNA通读提前终止密码子疾病中的截短蛋白 | |
CN104388463B (zh) | 黄瓜花叶病毒诱导的基因沉默系统及其应用 | |
US20130196374A1 (en) | Cis-acting element and use thereof | |
Chen et al. | An efficient genetic transformation system for Chinese medicine fungus Tolypocladium ophioglossoides | |
CN109456995A (zh) | 基因敲除质粒、细胞系及制备方法和应用 | |
CN105779482B (zh) | 一种基于dCas9的芽孢杆菌基因敲低载体质粒pBD1、构建及应用 | |
CN108148853B (zh) | 一种基因组编辑载体、其组成的基因组编辑系统及应用 | |
CN106520766A (zh) | 一种海藻内源组成型启动子及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |